Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 31 Mar 23 424B5 Prospectus supplement for primary offering
- 14 Sep 22 424B5 Prospectus supplement for primary offering
- 9 Mar 22 424B5 Prospectus supplement for primary offering
- 3 Jan 22 424B5 Prospectus supplement for primary offering
- 4 Jan 21 EFFECT Notice of effectiveness
-
23 Dec 20 F-3 Shelf registration (foreign)
AKTX similar filings
- 20 Oct 23 Shelf registration (foreign)
- 30 Aug 21 Shelf registration (foreign) (amended)
- 18 Aug 21 Shelf registration (foreign)
- 23 Dec 20 Shelf registration (foreign)
- 15 Apr 20 Shelf registration (foreign) (amended)
- 25 Mar 20 Shelf registration (foreign)
- 21 Feb 18 Shelf registration (foreign) (amended)
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Akari Therapeutics, Plc.
London, United Kingdom
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 30, 2020, relating to the consolidated financial statements of Akari Therapeutics, Plc. which is incorporated by reference in that Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
New York, New York
December 23, 2020